S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
66,000% upside on tiny biotech? (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
66,000% upside on tiny biotech? (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
66,000% upside on tiny biotech? (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
66,000% upside on tiny biotech? (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
OTCMKTS:BIOVF

Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price, News & Analysis

$25.50
+2.18 (+9.35%)
(As of 02/23/2024 ET)
Today's Range
$25.50
$25.50
50-Day Range
$23.32
$27.00
52-Week Range
$18.35
$27.00
Volume
330 shs
Average Volume
23 shs
Market Capitalization
N/A
P/E Ratio
35.41
Dividend Yield
N/A
Price Target
N/A

BIOVF stock logo

About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

BIOVF Stock Price History

BIOVF Stock News Headlines

Swedish Orphan Biovitrum AB (publ) (SWOBY)
Obama’s 2024 Confession
Barack Obama’s confession about the 2024 election just leaked online… In short, he’s worried Biden “could very well lose.” But before you think that means Trump will win… You should see the evidence I’ve found about an election shock that could come as soon as August 19th.
Invitation: Sobi's Q4 and FY 2023 report
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Swedish Orphan Biovitrum AB BIOVF
Sobi has completed the issuances of series C shares
Reminder: Invitation: Sobi's Q3 2023 report
Invitation: Sobi's Q3 2023 report
Sobi KOL investor event: the journey for Vonjo®
Invitation: Sobi's Q2 2023 report
See More Headlines
Receive BIOVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
2/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:BIOVF
CIK
N/A
Fax
N/A
Employees
1,612
Year Founded
2001

Profitability

Net Income
$227.10 million
Pretax Margin
16.72%

Debt

Sales & Book Value

Annual Sales
$2.09 billion
Cash Flow
$1.88 per share
Book Value
$8.91 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.51

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Guido Oelkers (Age 59)
    CEO & President
    Comp: $22.78M
  • Mr. Henrik Stenqvist (Age 57)
    Chief Financial Officer
  • Mr. Torbjörn Hallberg (Age 55)
    General Counsel & Head of Legal Affairs
  • Mr. Daniel Rankin (Age 44)
    Head of Strategy & Corporate Development
  • Ms. Lena Bjurner (Age 56)
    Head of Human Resources
  • Mr. Armin Reininger M.D. (Age 67)
    Ph.D., Senior Scientific & Medical Advisor
  • Mr. Norbert Oppitz (Age 57)
    Head of International
  • Mr. Sofiane Fahmy (Age 52)
    Head of Europe
  • Mr. Duane H. Barnes (Age 64)
    Head of North America
  • Mr. Mahmood Ladha (Age 60)
    Head of Strategic Transformation Operations














BIOVF Stock Analysis - Frequently Asked Questions

Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOVF shares.
View BIOVF analyst ratings
or view top-rated stocks.

How have BIOVF shares performed in 2024?

Swedish Orphan Biovitrum AB (publ)'s stock was trading at $26.25 at the beginning of 2024. Since then, BIOVF stock has decreased by 2.9% and is now trading at $25.4950.
View the best growth stocks for 2024 here
.

Are investors shorting Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 456,200 shares, a decline of 17.1% from the December 31st total of 550,100 shares. Based on an average daily trading volume, of 300 shares, the short-interest ratio is currently 1,520.7 days.
View Swedish Orphan Biovitrum AB (publ)'s Short Interest
.

How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter?

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) issued its earnings results on Thursday, February, 8th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.56 by $0.26. The company earned $643.39 million during the quarter, compared to analysts' expectations of $668.74 million. Swedish Orphan Biovitrum AB (publ) had a trailing twelve-month return on equity of 9.20% and a net margin of 10.95%.

How do I buy shares of Swedish Orphan Biovitrum AB (publ)?

Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BIOVF) was last updated on 2/25/2024 by MarketBeat.com Staff